What's new?

Data from Phase 1 Trial of RGX-202 Presented at 2020 ASCO Virtual Scientific Program   May 29, 2020 08:02 AM Eastern Daylight Time   NEW YORK--(BUSINESS WIRE)--RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is pr...

HAYWARD, Calif., May 28, 2020 – RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) for treating all stages of cancer, today announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada) to evaluate the safety and efficacy of KEYTRUDA® (pembrol...

Funding will enable accelerated development of a proprietary platform for the industrial production of Biotalys’ protein-based biocontrols   GHENT, Belgium, May 26, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today announced that it has been rewarded a €1.6 million resea...

Second regulator to approve "miR-AGE" Phase 2b/3 trial after clearance of French authorities (ANSM)   1,034-patient placebo-controlled trial to test oral ABX464's triple effect in COVID-19 patients: antiviral, anti-inflammatory and tissue repair Bpifrance provided €36 million non-dilutive funding for ABX464 COVID-1...

Arrabina™ Arabinoxylan GI tolerance no different than placebo   SCHAUMBURG, Ill., May 20, 2020 /PRNewswire/ -- Comet Bio announced today the successful completion of its randomized, placebo-controlled, crossover clinical trial evaluating the gastrointestinal (GI) tolerability and prebiotic effects of its Arabinoxyl...

Financing Accelerates Development of First-in-Class Therapies with Genetically Validated Mechanisms for Treatment of Autoimmune Diseases, Rare Diseases and Cancer   BOSTON, May 21, 2020 /PRNewswire/ -- HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allo...

French regulator, ANSM, as well as Ethics Committee, CPP, have cleared ABX464 for Phase 2b/3 “ miR-AGE ” testing

ABX464 is the only drug candidate with a potential triple action for COVID-19 treatment: antiviral, anti-inflammatory and tissue repair

Pre-clinical data from SR-Tiget, included in the alliance with Genespire, to be presented at ASGCT 23rd Annual Meeting